Loading stock data…
AZN.L
LSE14,044pGBX+88.00p (+0.63%)
Market OpenUpdated 10:10 AM EDT
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AstraZeneca PLC in the Healthcare sector is trading at 14,026p. The stock is currently 11% below its 52-week high of 15,732p, remaining 6.5% above its 200-day moving average. Technical signals show oversold RSI of 30 and bearish MACD signal, explaining why AZN.L maintains its current momentum and trend strength. The Whystock Score of 90/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 30) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price14,044p
Potential Downside
24.2%
Whystock Fair Value10,647p
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Buy
Mean target16,274p+15.9%
Range11,170p – 19,968p
Fundamentals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$223.44B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.77
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
162.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.84%
Volume
Today's trading volume
1.11M
Recent News
AstraZeneca PLC (AZN) Announces Positive Results From a Prespecified Interim Analysis of the I CAN Phase III Trial
AstraZeneca PLC (NYSE:AZN) is one of the best stem cell therapy stocks to buy. AstraZeneca PLC (NYSE:AZN) announced on April 21 that positive high-level results from a prespecified interim analysis of the I CAN Phase III trial showed that Ultomiris met its primary endpoint, exhibiting a statistically significant and clinically meaningful reduction of proteinuria. This was based on […]
AstraZeneca PLC (AZN): One of the Best Low Risk High Growth Firms
We just covered the 14 Best Low Risk High Growth Stocks to Buy Right Now and AstraZeneca PLC (NYSE:AZN) ranks 5th on this list. The growth story for AstraZeneca PLC (NYSE:AZN) is built on a massive, contractually visible expansion plan. Earlier this year, CEO Pascal Soriot reaffirmed the company’s goal to reach $80 billion in […]
Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
Will Lower Gardasil Sales Hurt MRK's Vaccines Sales in Q1 Earnings?
Gardasil's sharp sales slump in China and Japan puts Merck under pressure heading into Q1 earnings, as new vaccine Capvaxive gains momentum.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.